Evidence map›Paper›PMID 34001258›Full record

ArticleBMC research notes2021

Blue light inactivation of the enveloped RNA virus Phi6.

Petra Vatter, Katharina Hoenes, Martin Hessling

Abstract read
In one paragraph

Article in BMC research notes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Petra VatterInstitute of Medical Engineering and Mechatronics, Ulm University of Applied Sciences, Ulm, Germany.
Katharina HoenesInstitute of Medical Engineering and Mechatronics, Ulm University of Applied Sciences, Ulm, Germany.
Martin HesslingInstitute of Medical Engineering and Mechatronics, Ulm University of Applied Sciences, Ulm, Germany. Martin.Hessling@thu.de.ORCID http://orcid.org/0000-0002-4859-2864

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveUltraviolet radiation is known for its antimicrobial properties but unfortunately, it could also harm humans. Currently, disinfection techniques against SARS-CoV-2 are being sought that can be applied on air and surfaces and which do not pose a relevant thread to humans. In this study, the bacteriophage phi6, which like SARS-CoV-2 is an enveloped RNA virus, is irradiated with visible blue light at a wavelength of 455 nm.

resultsFor the first time worldwide, the antiviral properties of blue light around 455 nm can be demonstrated. With a dose of 7200 J/cm

Indexed as

COVID-19Ultraviolet RaysAntiviral AgentsHumansLightSARS-CoV-2Virus InactivationAntiviral AgentsBlue lightCoronavirusPhi6PhotoinactivationSARS-CoV-2

Identifiers

PMID34001258
PMCPMC8128082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.